Urine markers for detection and surveillance of non-muscle-invasive bladder cancer

European Urology

Volumn 60, Issue 3, 2011, Pages 484-492

  Tilki, Derya ^a   Burger, Maximilian ^b   Dalbagni, Guido ^c   Grossman, H Barton ^d   Hakenberg, Oliver W ^e   Palou, Juan ^f   Reich, Oliver ^g   Rouprêt, Morgan ^h   Shariat, Shahrokh F ⁱ   Zlotta, Alexandre R ^j  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF ROSTOCK   (Germany)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g Klinikum Harlaching   (Germany)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^j UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

Biomarkers; Bladder neoplasms; Detection; Diagnosis; Prediction; Urothelial carcinoma

Indexed keywords

AURORA A KINASE; BIOLOGICAL MARKER; BLADDER TUMOR ANTIGEN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; DNA FRAGMENT; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HYALURONIC ACID; HYALURONIDASE; MICRORNA; MICROSATELLITE DNA; NUCLEAR MATRIX PROTEIN 22; SINGLE STRANDED DNA; SURVIVIN; TELOMERASE; TRANSCIPTION FACTOR BLCA 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BLCA 4; TUMOR ANTIGEN; UNCLASSIFIED DRUG; URINE MARKER;

ANEUPLOIDY; BLADDER CANCER; BLADDER TUMOR ANTIGEN TEST; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER STAGING; CHROMOSOMAL INSTABILITY; CHROMOSOME 17; CHROMOSOME 3; CHROMOSOME 7; CHROMOSOME 9; DIAGNOSTIC ACCURACY; DNA METHYLATION; ENDOCYTOSCOPY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGENETICS; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HEMATURIA; HETEROZYGOSITY LOSS; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE TEST; INFORMATION RETRIEVAL; NONMUSCLE INVASIVE BLADDER CANCER; NUCLEAR MATRIX PROTEIN 22 TEST; POINT OF CARE TESTING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE; URINALYSIS; URINE CYTOLOGY;

CYSTOSCOPY; HUMANS; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 79960991339     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.05.053     Document Type: Review

References (110)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010;60:227-300.
2. Witjes JA, Hendricksen K. Intravesical pharmacotherapy for non- muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol 2008;53:45-52. (Pubitemid 350167566)
3. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non- muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997-1008.
4. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003;61:109-18, discussion 118.
5. Kinders R, Jones T, Root R, et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res 1998;4:2511-20. (Pubitemid 28477919)
6. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998;52:398-402. (Pubitemid 28399904)
7. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999;162:53-7. (Pubitemid 29420879)
8. Wiener HG, Mian C, Haitel A, Pycha A, Schatzl G, Marberger M. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 1998;159:1876-80.
9. Leyh H, Marberger M, Conort P, et al. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol 1999;35:52-6. (Pubitemid 29080552)
10. Leyh H, Mazeman E. Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer. Eur Urol 1997;32:425-8. (Pubitemid 27501040)
11. Nasuti JF, Gomella LG, Ismial M, Bibbo M. Utility of the BTA stat test kit for bladder cancer screening. Diagn Cytopathol 1999;21:27-9. (Pubitemid 29294047)
12. Oge O, Kozaci D, Gemalmaz H. The BTA stat test is nonspecific for hematuria: an experimental hematuria model. J Urol 2002;167: 1318-9, discussion 1319-20.
13. Raitanen MP. The role of BTA stat test in follow-up of patients with bladder cancer: results from Finn Bladder studies. World J Urol 2008;26:45-50.
14. Malkowicz SB. The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer. Urol Clin North Am 2000;27:63-73, ix.
15. Thomas L, Leyh H, Marberger M, et al. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem 1999;45:472-7. (Pubitemid 29165956)
16. Abbate I, D'Introno A, Cardo G, et al. Comparison of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer. Anticancer Res 1998;18:3803-5. (Pubitemid 28564270)
17. Babjuk M, Soukup V, Pesl M, et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology 2008;71:718-22. (Pubitemid 351447297)
18. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology 1997;50:882-7.
19. Heicappell R, Wettig IC, Schostak M, et al. Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder. Eur Urol 1999;35:81-7. (Pubitemid 29080555)
20. Irani J, Desgrandchamps F, Millet C, et al. BTA stat and BTA TRAK: a comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder. Eur Urol 1999;35:89-92. (Pubitemid 29080238)
21. Mahnert B, Tauber S, Kriegmair M, et al. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)-useful diagnostic tools in the diagnosis of urinary bladder cancer? Clin Chem Lab Med 2003;41: 104-10.
22. Tsui KH, Chen SM, Wang TM, et al. Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China. Asian J Androl 2007;9:711-5.
23. Fradet Y, Lockhard C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. Can J Urol 1997;4:400-5.
24. Greene KL, Berry A, Konety BR. Diagnostic utility of the Immuno- Cyt/uCyt+ test in bladder cancer. Rev Urol 2006;8:190-7.
25. Li HX, Li M, Li CL, et al. ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study. Anal Quant Cytol Histol 2010; 32:45-52.
26. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 1999;161:1486-9. (Pubitemid 29420801)
27. Olsson H, Zackrisson B. ImmunoCyt a useful methodin the follow-up protocol for patients with urinary bladder carcinoma. Scand J Urol Nephrol 2001;35:280-2. (Pubitemid 32906848)
28. Vriesema JL, Atsma F, Kiemeney LA, Peelen WP, Witjes JA, Schalken JA. Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology 2001;58:367-71. (Pubitemid 32816352)
29. Pfister C, Chautard D, Devonec M, et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 2003;169:921-4. (Pubitemid 36188123)
30. Hughes JH, Katz RL, Rodriguez-Villanueva J, et al. Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder. Diagn Cytopathol 1999;20:285-90. (Pubitemid 29205522)
31. Miyanaga N, Akaza H, Tsukamoto T, et al. Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria. Int J Urol 1999;6:173-7. (Pubitemid 30406838)
32. Ramakumar S, Bhuiyan J, Besse JA, et al. Comparison of screening methods in the detection of bladder cancer. J Urol 1999;161: 388-94.
33. Soloway MS, Briggman V, Carpinito GA, et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996;156:363-7. (Pubitemid 126445343)
34. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998;159:394-8. (Pubitemid 28049240)
35. Mansoor I, Calam RR, Al-Khafaji B. Role of urinary NMP-22 combined with urine cytology in follow-up surveillance of recurring superficial bladder urothelial carcinoma. Anal Quant Cytol Histol 2008;30:25-32. (Pubitemid 351312097)
36. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005;293: 810-6. (Pubitemid 40250364)
37. Shariat SF, Savage C, Chromecki TF, et al. Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. Cancer. In press.
38. Junker K, Boerner D, Schulze W, Utting M, Schubert J, Werner W. Analysis of genetic alterations in normal bladder urothelium. Urology 2003;62:1134-8. (Pubitemid 37510107)
39. Friedrich MG, Hellstern A, Toma MI, Hammerer P, Huland H. Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence? Eur Urol 2003;43:146-51, discussion 150-1.
40. Halling KC. Vysis UroVysion for the detection of urothelial carcinoma. Expert Rev Mol Diagn 2003;3:507-19. (Pubitemid 36859297)
41. Halling KC, King W, Sokolova IA, et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002;167: 2001-6. (Pubitemid 34309646)
42. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 2008;26:646-51.
43. Skacel M, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003;169:2101-5. (Pubitemid 36576726)
44. Gofrit ON, Zorn KC, Silvestre J, et al. The predictive value of multitargeted fluorescent in-situ hybridization in patients with history of bladder cancer. Urol Oncol 2008;26:246-9. (Pubitemid 351608575)
45. Sarosdy MF, Schellhammer P, Bokinsky G, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002;168:1950-4.
46. Daniely M, Rona R, Kaplan T, et al. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology. Cancer 2007;111:517-24. (Pubitemid 350304904)
47. Daniely M, Rona R, Kaplan T, et al. Combined analysis of morphology and fluorescence in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine samples. Urology 2005;66:1354-9. (Pubitemid 41797331)
48. Park HS, Park WS, Bondaruk J, et al. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst 2008;100:1401-11.
49. Myers-Irvin JM, Landsittel D, Getzenberg RH. Use of the novel marker BLCA-1 for the detection of bladder cancer. J Urol 2005; 174:64-8. (Pubitemid 40825673)
50. Konety BR, Nguyen TS, Dhir R, et al. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res 2000;6:2618-25. (Pubitemid 30482096)
51. Van Le TS, Miller R, Barder T, Babjuk M, Potter DM, Getzenberg RH. Highly specific urine-based marker of bladder cancer. Urology 2005;66:1256-60. (Pubitemid 41797301)
52. Van Le TS, Myers J, Konety BR, Barder T, Getzenberg RH. Functional characterization of the bladder cancer marker, BLCA-4. Clin Cancer Res 2004;10:1384-91. (Pubitemid 38365233)
53. Konety BR, Nguyen TS, Brenes G, et al. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J Urol 2000;164:634-9. (Pubitemid 30637591)
54. Tilki D, Singer BB, Shariat SF, et al. CEACAM1: a novel urinary marker for bladder cancer detection. Eur Urol 2010;57:648-54.
55. Yu J, Zhu T, Wang Z, et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 2007;13:7296-304.
56. Friedrich MG, Weisenberger DJ, Cheng JC, et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 2004;10:7457-65 (Pubitemid 39557507)
57. Rouprêt M, Hupertan V, Yates DR, et al. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. BJU Int 2008;101:1448-53. (Pubitemid 351623989)
58. Hoque MO, Begum S, Topaloglu O, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006;98:996-1004. (Pubitemid 44288164)
59. Phe V, Cussenot O, Rouprêt M. Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. BJU Int 2009;104:896-901.
60. Renard I, Joniau S, van Cleynenbreugel B, et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur Urol 2010;58:96-104.
61. van Oers JM, Lurkin I, van Exsel AJ, et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 2005;11:7743-8. (Pubitemid 41611617)
62. Zuiverloon TC, van der Aa MN, van der Kwast TH, et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res 2010;16:3011-8.
63. Lokeshwar VB, Obek C, Soloway MS, Block NL. Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res 1997;57:773-7. (Pubitemid 27085665)
64. Lokeshwar VB, Block NL. HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade. Urol Clin North Am 2000;27:53-61.
65. Pham HT, Block NL, Lokeshwar VB. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res 1997;57:778-83. (Pubitemid 27085666)
66. Hautmann SH, Lokeshwar VB, Schroeder GL, et al. Elevated tissue expression of hyaluronic acid and hyaluronidase validates the HAHAase urine test for bladder cancer. J Urol 2001;165:2068-74.
67. Hautmann S, Toma M, Lorenzo Gomez MF, et al. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur Urol 2004;46:466-71. (Pubitemid 39200854)
68. van Rhijn BW, Lurkin I, Kirkels WJ, van der Kwast TH, Zwarthoff EC. Microsatellite analysis-DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial. Cancer 2001;92:768-75. (Pubitemid 32783061)
69. Czerniak B, Chaturvedi V, Li L, et al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 1999;18:1185-96. (Pubitemid 29085991)
70. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. Allelotype of human bladder cancer. Cancer Res 1994;54:531-8. (Pubitemid 24053197)
71. von Knobloch R, Hegele A, Brandt H, Olbert P, Heidenreich A, Hofmann R. Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int J Cancer 2001;94:67-72. (Pubitemid 32801754)
72. van der Aa MN, Zwarthoff EC, Steyerberg EW, et al. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]). Eur Urol 2009;55:659-67.
73. Catto JW, Alcaraz A, Bjartell AS, et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 2011;59:671-81.
74. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007;9:654-9. (Pubitemid 47214727)
75. Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA- 182 are related to urinary bladder cancer. Urol Oncol 2010; 28:655-61.
76. Catto JW, Miah S, Owen HC, et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 2009;69:8472-81.
77. Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 2008;26:59-65.
78. Schultz IJ, Kiemeney LA, Karthaus HF, et al. Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin Chem 2004;50: 1425-8. (Pubitemid 38970655)
79. Shariat SF, Casella R, Khoddami SM, et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004;171:626-30. (Pubitemid 38090444)
80. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001;285:324-8. (Pubitemid 32095036)
81. Weikert S, Christoph F, Schrader M, Krause H, Miller K, Muller M. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 2005;116: 100-4. (Pubitemid 40827761)
82. Horstmann M, Bontrup H, Hennenlotter J, et al. Clinical experience with survivin as a biomarker for urothelial bladder cancer. World J Urol 2010;28:399-404.
83. Blackburn EH. Telomeres and their synthesis. Harvey Lect 1990; 86:1-18.
84. Blackburn EH. Structure and function of telomeres. Nature 1991; 350:569-73. (Pubitemid 21912269)
85. Greider CW. Telomere length regulation. Annu Rev Biochem 1996;65:337-65. (Pubitemid 26250613)
86. Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989; 59:521-9. (Pubitemid 19284465)
87. Ito H, Kyo S, Kanaya T, Takakura M, Inoue M, Namiki M. Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. Clin Cancer Res 1998;4:1603-8. (Pubitemid 28304720)
88. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
89. De Kok JB, Schalken JA, Aalders TW, Ruers TJ, Willems HL, Swinkels DW. Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas. Int J Cancer 2000;87:217-20. (Pubitemid 30434348)
90. Melissourgos N, Kastrinakis NG, Davilas I, Foukas P, Farmakis A, Lykourinas M. Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker. Urology 2003;62:362-7. (Pubitemid 36952107)
91. Cassel A, Rahat MA, Lahat N, Lindenfeld N, Mecz Y, Stein A. Telomerase activity and cytokeratin 20 as markers for the detection and followup of transitional cell carcinoma: an unfulfilled promise. J Urol 2001;166:841-4. (Pubitemid 32750960)
92. Cheng CW, Chueh SC, Chern HD. Diagnosis of bladder cancer using telomerase activity in voided urine. J Formos Med Assoc 2000;99: 920-5.
93. Dalbagni G, Han W, Zhang ZF, et al. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer. Clin Cancer Res 1997;3:1593-8. (Pubitemid 27431568)
94. Kavaler E, Landman J, Chang Y, Droller MJ, Liu BC. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer 1998;82:708-14. (Pubitemid 28090283)
95. Lee DH, Yang SC, Hong SJ, Chung BH, Kim IY. Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. Clin Cancer Res 1998;4:535-8. (Pubitemid 28193550)
96. Mayfield MP, Shah T, Flannigan GM, Hamilton Stewart PA, Bibby MC. Telomerase activity in malignant and benign bladder conditions. Int J Mol Med 1998;1:835-40.
97. Muller M, Krause H, Heicappell R, Tischendorf J, Shay JW, Miller K. Comparison of human telomerase RNA and telomerase activity in urine for diagnosis of bladder cancer. Clin Cancer Res 1998;4: 1949-54. (Pubitemid 28369180)
98. Wu XX, Kakehi Y, Takahashi T, Habuchi T, Ogawa O. Telomerase activity in urine after transurethral resection of superficial bladder cancer and early recurrence. Int J Urol 2000;7:210-7. (Pubitemid 30330700)
99. Yokota K, Kanda K, Inoue Y, Kanayama H, Kagawa S. Semi-quantitative analysis of telomerase activity in exfoliatedhuman urothelial cells and bladder transitional cell carcinoma. Br J Urol 1998;82: 727-32. (Pubitemid 28497759)
100. Lee MY, Tsou MH, Cheng MH, Chang DS, Yang AL, Ko JS. Clinical application of NMP22 and urinary cytology in patients with hematuria or a history of urothelial carcinoma. World J Urol 2000;18:401-5.
101. Weikert S, Krause H, Wolff I, et al. Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer. Int J Cancer 2005;117:274-80. (Pubitemid 41377448)
102. Sanchini MA, Gunelli R, Nanni O, et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA 2005;294:2052-6. (Pubitemid 41539938)
103. Heicappell R, Schostak M, Muller M, Miller K. Evaluation of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the urinary bladder. Scand J Clin Lab Invest 2000;60: 275-82. (Pubitemid 30616610)
104. Mian C, Lodde M, Haitel A, Egarter Vigl E, Marberger M, Pycha A. Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urology 2000;56:228-31. (Pubitemid 30495572)
105. Babjuk M, Koštířová M, Mudra K, et al. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder. Eur Urol 2002;41:34-9.
106. Hakenberg OW, Fuessel S, Richter K, et al. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma. Urology 2004;64:1121-6. (Pubitemid 39647052)
107. Lotan Y, Shariat SF, Schmitz-Drager BJ, et al. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol 2010;28:441-8.
108. Roobol MJ, Bangma CH, el Bouazzaoui S, Franken-Raab CG, Zwarthoff EC. Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project). Urol Oncol 2010;28:686-90.
109. Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. Eur Urol 2007;52:1601-9. (Pubitemid 350052431)
110. Bravaccini S, Casadio V, Gunelli R, et al. Combining cytology, TRAP assay, and FISH analysis for the detection of bladder cancer in symptomatic patients. Ann Oncol. In press.